DDX3X and neoplasm: Inhibiting ATP-dependent RNA helicase DDX3X’s ATP binding domain with the small molecule RK-33 was one of choices, and the effect was discovered to synergize with radiotherapy to reduce tumor cells’ proliferation in vitro and in vivo [29].